...
首页> 外文期刊>Scientific reports. >Cost-effectiveness of hemodialysis and peritoneal dialysis: A national cohort study with 14 years follow-up and matched for comorbidities and propensity score
【24h】

Cost-effectiveness of hemodialysis and peritoneal dialysis: A national cohort study with 14 years follow-up and matched for comorbidities and propensity score

机译:血液透析和腹膜透析的成本效益:国家队列与14年后续随访,匹配合并症和倾向评分

获取原文
           

摘要

Although treatment for the dialysis population is resource intensive, a cost-effectiveness analysis comparing hemodialysis (HD) and peritoneal dialysis (PD) by matched pairs is still lacking. After matching for clinical characteristics and propensity scores, we identified 4,285 pairs of incident HD and PD patients from a Taiwanese national cohort during 1998-2010. Survival and healthcare expenditure were calculated by data of 14-year follow-up and subsequently extrapolated to lifetime estimates under the assumption of constant excess hazard. We performed a cross-sectional EQ-5D survey on 179 matched pairs of prevalent HD and PD patients of varying dialysis vintages from 12 dialysis units. The product of survival probability and the mean utility value at each time point (dialysis vintage) were summed up throughout lifetime to obtain the quality-adjusted life expectancy (QALE). The results revealed the estimated life expectancy between HD and PD were nearly equal (19.11 versus 19.08 years). The QALE's were also similar, whereas average lifetime healthcare costs were higher in HD than PD (237,795 versus 204,442 USD) and the cost-effectiveness ratios for PD and HD were 13,681 and 16,643 USD per quality-adjusted life year, respectively. In conclusion, PD is more cost-effective than HD, of which the major determinants were the costs for the dialysis modality and its associated complications.
机译:虽然对透析人群的治疗是资源密集型的,但仍然缺乏对比较血液透析(HD)和腹膜透析(PD)的成本效益分析。在临床特征和倾向分数匹配后,我们在1998 - 2010年期间鉴定了来自台湾国家队列的4,285对事件HD和PD患者。通过14年后续的数据计算生存和医疗保健支出,随后在持续过度危险的假设下推断到终身估计。我们对179对常见的HDL和PD患者进行了横截面EQ-5D调查,从12个透析单元不同透析葡萄酒。生存概率的产物和每个时间点(透析复古)的平均效用价值在整个寿命中总结,以获得质量调整的寿命(QALE)。结果表明,高清和Pd之间的估计预期寿命几乎相等(19.11与19.08年)。 QALE也是相似的,而平均终身医疗保健成本高于PD(237,795与204,442美元),PD和HD的成本效益比分别为13,681和16,643美元,每年质量调整年份。总之,PD比HD更具成本效益,其中主要决定因素是透析形式及其相关并发症的成本。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号